Structure and luminescence properties of a new Cu-Cyteamine (Cu-Cy) crystal material are provided. The crystal structure of the Cu-Cy is determined by single crystal X-ray diffraction. It is found that the compound crystallizes in the monoclinic space group C2/c and cell parameters are a=7.5510(4) , b=16.9848(7) , c=7.8364(4) , =104.798(3). The new Cu-Cy crystal material of the invention is also useful for treatment of cancer.

A radiopharmaceutical composition is here described comprising as the active ingredient copper-64 in ionic form (64Cu++), in combination with suitable excipients, and/or diluents, having radioconcentration comprised between 50 and 3,500 MBq/mL at calibration time. Such radiopharmaceutical composition is useful in a method for treating a subject affected by a neoplasia. Such method may comprise a step for evaluating the eligibility of a patient for the treatment, in which 64Cu++ cellular uptake is detected. In case no uptake is detectable, the treatment is not advisable. In case radioactive copper uptake from cancer lesions is detectable, this has a predictive value of response to treatment and the subject is selected for the treatment. If the patient is eligible for the treatment and is selected for the treatment, the method further comprises a step of treating cancer in said subject by administering a therapeutically effective amount of the same 64Cu++ salt.

A method for producing .sup.99mTc may include: providing a solution comprising .sup.100Mo-molybdate-ions; providing a proton beam having an energy suitable for inducing a .sup.100Mo(p,2n).sup.99mTc-nuclear reaction when exposing .sup.100Mo-molybdate-ions; exposing the solution to the proton beams and inducing a .sup.100Mo(p,2n).sup.99mTc-nuclear reaction; and applying an extraction method for extracting the .sup.99mTc from the solution. Further, a device for producing .sup.99mTc may include: a solution with .sup.100Mo-molybdate-ions; an accelerator for providing a proton beam with energy which is suitable for inducing a .sup.100Mo(p,2n).sup.99mTc-nuclear reaction when exposing .sup.100Mo-molybdate-ions, for exposing the solution and for inducing a .sup.100Mo(p,2n).sup.99mTc-nuclear reaction; and an extraction step for extracting .sup.99mTc from the solution.

The present invention provides a .sup.99mTc-tetrofosmin radiopharmaceutical composition comprising tetrofosmin and a radioprotectant at a particular range of molar ratios. A kit and a multi-dose kit for the preparation of the radiopharmaceutical composition of the invention are also provided, as well as a process for the preparation of multiple unit patient doses of the radiopharmaceutical composition and a unit dose of the radiopharmaceutical composition.

The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer. The composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide according to the present invention, which comprises the compound represented by formula 1 (.sup.99mTc-alpha-hydroxy acid) having alpha-hydroxy acid labeled with .sup.99mTc, enables the detection or concentration measurement of hydrogen sulfide in in-vitro and in-vivo levels and, as such, can be advantageously used for detecting hydrogen sulfide and measuring a concentration of hydrogen sulfide and furthermore for discovering biological roles of hydrogen sulfide in vivo, especially, for detecting, imaging, and quantitatively measuring hydrogen sulfide in a disease selected from the group consisting of angiogenesis, inflammation, cancer, Alzheimer's disease, cardiovascular ischemia, and cerebrovascular ischemia, or in hypoxic tissues.

This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging.

The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

A method of accumulating radium radionuclides, comprising providing a first solution including thorium radionuclides and a thorium-binding extractant, wherein the first solution does not bind to radium, allowing a portion of the thorium radionuclides in the first solution to decay into radium atoms and collecting radium atoms resulting from the decay. The collected radium atoms may be included in a solution in which brachytherapy sources are dipped, in a manner which collects the radium atoms onto the source.

A radiotherapy source includes a base suitable for radiotherapy, a manganese oxide coating over the base, and radium atoms attached to the manganese oxide coating. The manganese oxide coating may comprise manganese dioxide (MnO.sub.2), manganese (II) oxide (MnO), manganese (II,III) oxide (Mn.sub.3O.sub.4) and/or other manganese oxides. Methods for producing radiotherapy sources are also disclosed.